Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.

Haywood LJ, Davis BR, Piller LB, Simpson LM, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT Jr; ALLHAT Collaborative Research Group.

J Natl Med Assoc. 2018 Aug;110(4):343-351. doi: 10.1016/j.jnma.2017.07.003. Epub 2017 Jul 24.

PMID:
30126559
2.

An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target.

Coopes A, Henry CE, Llamosas E, Ford CE.

Endocr Relat Cancer. 2018 Aug 9. pii: ERC-18-0112. doi: 10.1530/ERC-18-0112. [Epub ahead of print]

PMID:
30093601
3.

Maternal Decision-Making and Uptake of Health Services for the Prevention of Mother-to-Child HIV Transmission: A Secondary Analysis.

Ford CE, Coetzee D, Winston J, Chibwesha CJ, Ekouevi DK, Welty TK, Tih PM, Maman S, Stringer EM, Stringer JSA, Chi BH.

Matern Child Health J. 2018 Jul 18. doi: 10.1007/s10995-018-2588-9. [Epub ahead of print]

PMID:
30022401
4.

Low agreement among reviewers evaluating the same NIH grant applications.

Pier EL, Brauer M, Filut A, Kaatz A, Raclaw J, Nathan MJ, Ford CE, Carnes M.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):2952-2957. doi: 10.1073/pnas.1714379115. Epub 2018 Mar 5.

5.

I-AbACUS: a Reliable Software Tool for the Semi-Automatic Analysis of Invasion and Migration Transwell Assays.

Cortesi M, Llamosas E, Henry CE, Kumaran RA, Ng B, Youkhana J, Ford CE.

Sci Rep. 2018 Feb 28;8(1):3814. doi: 10.1038/s41598-018-22091-5.

6.

ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.

Henry CE, Llamosas E, Daniels B, Coopes A, Tang K, Ford CE.

Gynecol Oncol. 2018 Mar;148(3):576-584. doi: 10.1016/j.ygyno.2018.01.025. Epub 2018 Feb 1.

PMID:
29395309
7.

Laughter and the Management of Divergent Positions in Peer Review Interactions.

Raclaw J, Ford CE.

J Pragmat. 2017 May;113:1-15. doi: 10.1016/j.pragma.2017.03.005. Epub 2017 Mar 29.

8.

Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.

Haywood LJ, Davis BR, Piller LB, Cushman WC, Cutler JA, Ford CE, Simpson LM, Ghosh A, Soliman EZ, Wright JT Jr; ALLHAT Collaborative Research Group.

J Natl Med Assoc. 2017 Autumn;109(3):172-181. doi: 10.1016/j.jnma.2017.02.005. Epub 2017 Mar 18.

PMID:
28987246
9.

Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma.

Warton K, Yuwono NL, Cowley MJ, McCabe MJ, So A, Ford CE.

Mol Diagn Ther. 2017 Oct;21(5):563-570. doi: 10.1007/s40291-017-0284-x.

PMID:
28631163
10.

'Your comments are meaner than your score': score calibration talk influences intra- and inter-panel variability during scientific grant peer review.

Pier EL, Raclaw J, Kaatz A, Brauer M, Carnes M, Nathan MJ, Ford CE.

Res Eval. 2017 Jan;26(1):1-14. doi: 10.1093/reseval/rvw025. Epub 2017 Feb 14.

11.

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.

Henry CE, Emmanuel C, Lambie N, Loo C, Kan B, Kennedy CJ, de Fazio A, Hacker NF, Ford CE.

Transl Oncol. 2017 Jun;10(3):346-356. doi: 10.1016/j.tranon.2017.01.014. Epub 2017 Mar 23.

12.

Association between chronic kidney disease and cancer mortality: A report from the ALLHAT.

Chen DP, Davis BR, Simpson LM, Cushman WC, Cutler JA, Dobre M, Ford CE, Louis GT, Muntner P, Oparil S, Piller LB, Pressel SL, Sarnak MJ, Whelton PK, Wright JT, Rahman M.

Clin Nephrol. 2017 Jan;87 (2017)(1):11-20.

PMID:
27900942
13.

Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Ma SS, Henry CE, Llamosas E, Higgins R, Daniels B, Hesson LB, Hawkins NJ, Ward RL, Ford CE.

Virchows Arch. 2017 Jan;470(1):99-108. doi: 10.1007/s00428-016-2019-5. Epub 2016 Sep 8. Erratum in: Virchows Arch. 2016 Dec;469(6):717.

PMID:
27631337
14.

Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Ma SS, Henry CE, Llamosas E, Higgins R, Daniels B, Hesson LB, Hawkins NJ, Ward RL, Ford CE.

Virchows Arch. 2016 Dec;469(6):717. Epub 2016 Oct 29. No abstract available.

PMID:
27796585
15.

Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors.

Hesson LB, Ng B, Zarzour P, Srivastava S, Kwok CT, Packham D, Nunez AC, Beck D, Ryan R, Dower A, Ford CE, Pimanda JE, Sloane MA, Hawkins NJ, Bourke MJ, Wong JW, Ward RL.

Mol Cancer Res. 2016 Dec;14(12):1217-1228. Epub 2016 Sep 26.

16.

ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.

Ma SS, Srivastava S, Llamosas E, Hawkins NJ, Hesson LB, Ward RL, Ford CE.

BMC Cancer. 2016 Jul 20;16:508. doi: 10.1186/s12885-016-2576-7.

17.

Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial.

Whittle J, Yamal JM, Williamson JD, Ford CE, Probstfield JL, Beard BL, Marginean H, Hamilton BP, Suhan PS, Davis BR; ALLHAT Collaborative Research Group.

BMC Health Serv Res. 2016 Jul 8;16:236. doi: 10.1186/s12913-016-1471-x.

18.

Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children in Zambia: A Clinical Trial Protocol.

Chibwesha CJ, Ford CE, Mollan KR, Stringer JS.

J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S197-201. doi: 10.1097/QAI.0000000000001050.

19.

Selection and visualisation of outcome measures for complex post-acute acquired brain injury rehabilitation interventions.

Ford CE, Malley D, Bateman A, Clare IC, Wagner AP, Gracey F.

NeuroRehabilitation. 2016 Jun 23;39(1):65-79. doi: 10.3233/NRE-161339.

20.

Comment on: Wnt5a inhibited human trophoblast cell line HTR8/SVneo invasion: implications for early placentation and preeclampsia.

van Zuylen WJ, Ford CE, Rawlinson WD.

J Matern Fetal Neonatal Med. 2017 May;30(9):1085-1086. doi: 10.1080/14767058.2016.1203411. Epub 2016 Jul 11. No abstract available.

PMID:
27315538
21.

The Wnt pathway: a key network in cell signalling dysregulated by viruses.

van Zuylen WJ, Rawlinson WD, Ford CE.

Rev Med Virol. 2016 Sep;26(5):340-55. doi: 10.1002/rmv.1892. Epub 2016 Jun 8. Review.

PMID:
27273590
22.

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.

Henry CE, Llamosas E, Djordjevic A, Hacker NF, Ford CE.

Oncogenesis. 2016 May 30;5(5):e226. doi: 10.1038/oncsis.2016.32.

23.

The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study.

Do AN, Lynch AI, Claas SA, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Tiwari HK, Arnett DK, Irvin MR.

J Hum Hypertens. 2016 Sep;30(9):549-54. doi: 10.1038/jhh.2015.121. Epub 2016 Jan 21.

24.

Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).

Alderman MH, Davis BR, Piller LB, Ford CE, Baraniuk MS, Pressel SL, Assadi MA, Einhorn PT, Haywood LJ, Ilamathi E, Oparil S, Retta TM; ALLHAT Collaborative Research Group.

Am J Cardiol. 2016 Jan 1;117(1):105-15. doi: 10.1016/j.amjcard.2015.10.012. Epub 2015 Oct 19.

25.

Human Cytomegalovirus Modulates Expression of Noncanonical Wnt Receptor ROR2 To Alter Trophoblast Migration.

van Zuylen WJ, Ford CE, Wong DD, Rawlinson WD.

J Virol. 2015 Nov 11;90(2):1108-15. doi: 10.1128/JVI.02588-15. Print 2016 Jan 15.

26.

Wnt signalling in gynaecological cancers: A future target for personalised medicine?

Ford CE, Henry C, Llamosas E, Djordjevic A, Hacker N.

Gynecol Oncol. 2016 Feb;140(2):345-51. doi: 10.1016/j.ygyno.2015.09.085. Epub 2015 Sep 30. Review.

PMID:
26432042
27.

The effect of an intervention to break the gender bias habit for faculty at one institution: a cluster randomized, controlled trial.

Carnes M, Devine PG, Baier Manwell L, Byars-Winston A, Fine E, Ford CE, Forscher P, Isaac C, Kaatz A, Magua W, Palta M, Sheridan J.

Acad Med. 2015 Feb;90(2):221-30. doi: 10.1097/ACM.0000000000000552.

28.

The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study.

Do AN, Irvin MR, Lynch AI, Claas SA, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Tiwari HK, Limdi NA, Arnett DK.

Front Pharmacol. 2014 Sep 16;5:210. doi: 10.3389/fphar.2014.00210. eCollection 2014.

29.

Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.

Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE.

J Cancer Res Clin Oncol. 2015 Feb;141(2):243-54. doi: 10.1007/s00432-014-1824-y. Epub 2014 Sep 11.

PMID:
25209439
30.

Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study.

Sørensen IF, Vazquez AI, Irvin MR, Sørensen P, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Arnett DK.

Pharmacogenet Genomics. 2014 Nov;24(11):556-63. doi: 10.1097/FPC.0000000000000088.

31.

The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Ford CE, Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J, Caduff R, Ward RL, Heinzelmann-Schwarz V.

Gynecol Oncol. 2014 Aug;134(2):338-45. doi: 10.1016/j.ygyno.2014.06.004. Epub 2014 Jun 10.

PMID:
24924122
32.

Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?

Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD.

J Clin Hypertens (Greenwich). 2013 Dec;15(12):941. doi: 10.1111/jch.12220. Epub 2013 Oct 30. No abstract available.

33.

Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT.

Lynch AI, Irvin MR, Davis BR, Ford CE, Eckfeldt JH, Arnett DK.

Int J Hypertens. 2013;2013:578578. doi: 10.1155/2013/578578. Epub 2013 Oct 31.

34.

Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.

Phillips W, Piller LB, Williamson JD, Whittle J, Jafri SZ, Ford CE, Einhorn PT, Oparil S, Furberg CD, Grimm RH Jr, Alderman MH, Davis BR, Probstfield JL; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2013 Nov;15(11):825-32. doi: 10.1111/jch.12180. Epub 2013 Aug 7.

35.

Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2013 Aug;15(8):542-54. doi: 10.1111/jch.12139. Epub 2013 Jun 10.

36.

The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.

Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE.

BMC Cancer. 2013 Apr 2;13:174. doi: 10.1186/1471-2407-13-174.

37.

Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.

Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT Jr; ALLHAT Collaborative Research Group.

Hypertension. 2013 May;61(5):977-86. doi: 10.1161/HYPERTENSIONAHA.111.00213. Epub 2013 Mar 25.

38.

The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.

Ford CE, Jary E, Ma SS, Nixdorf S, Heinzelmann-Schwarz VA, Ward RL.

PLoS One. 2013;8(1):e54362. doi: 10.1371/journal.pone.0054362. Epub 2013 Jan 11.

39.

The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis.

Ford CE, Qian Ma SS, Quadir A, Ward RL.

Int J Cancer. 2013 Aug 15;133(4):779-87. doi: 10.1002/ijc.27984. Epub 2013 Jan 10. Review.

40.

Performance of Clinical Algorithms for Smear-Negative Tuberculosis in HIV-Infected Persons in Ho Chi Minh City, Vietnam.

Nguyen DT, Nguyen HQ, Beasley RP, Ford CE, Hwang LY, Graviss EA.

Tuberc Res Treat. 2012;2012:360852. doi: 10.1155/2012/360852. Epub 2012 Nov 25.

41.

How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?

Proschan M, Ford CE, Cutler JA, Graumlich JF, Pavlik V, Cushman WC, Davis BR, Alderman MH, Gordon D, Furberg CD, Franklin SS, Blumenthal SS, Castaldo RS, Preston RA; LHAT Collaborative Research Group.

Stat Med. 2013 Feb 28;32(5):884-97. doi: 10.1002/sim.5580. Epub 2012 Sep 7.

PMID:
22961832
42.

Promoting Institutional Change Through Bias Literacy.

Carnes M, Devine PG, Isaac C, Manwell LB, Ford CE, Byars-Winston A, Fine E, Sheridan JT.

J Divers High Educ. 2012 Jun;5(2):63-77. Epub 2012 Jan 19.

43.

RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.

Lynch AI, Irvin MR, Boerwinkle E, Davis BR, Vaughan LK, Ford CE, Aissani B, Eckfeldt JH, Arnett DK, Shrestha S.

Pharmacogenomics J. 2013 Aug;13(4):330-4. doi: 10.1038/tpj.2012.22. Epub 2012 Jun 5.

44.

Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.

Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT Jr, Barzilay JI, Brown CD, Colon PJ Sr, Fine LJ, Grimm RH Jr, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R; ALLHAT Collaborative Research Group.

Clin J Am Soc Nephrol. 2012 Jun;7(6):989-1002. doi: 10.2215/CJN.07800811. Epub 2012 Apr 5.

45.

Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.

Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Leiendecker-Foster C, Arnett DK.

PLoS One. 2012;7(3):e34217. doi: 10.1371/journal.pone.0034217. Epub 2012 Mar 28.

46.

Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2012 May;59(5):926-33. doi: 10.1161/HYPERTENSIONAHA.111.180554. Epub 2012 Mar 19.

47.

Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.

Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J, Oparil S, Piller LB, Simmons DL, Sweeney ME, Whelton PK, Wong ND, Wright JT Jr; ALLHAT Collaborative Research Group.

Circ Cardiovasc Qual Outcomes. 2012 Mar 1;5(2):153-62. doi: 10.1161/CIRCOUTCOMES.111.962522. Epub 2012 Mar 6.

48.

Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.

Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Arnett DK.

Pharmacogenet Genomics. 2012 May;22(5):355-66. doi: 10.1097/FPC.0b013e3283516ff8.

49.

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.

Jacob F, Ukegjini K, Nixdorf S, Ford CE, Olivier J, Caduff R, Scurry JP, Guertler R, Hornung D, Mueller R, Fink DA, Hacker NF, Heinzelmann-Schwarz VA.

PLoS One. 2012;7(2):e31885. doi: 10.1371/journal.pone.0031885. Epub 2012 Feb 21.

50.

Securing recipiency in workplace meetings: Multimodal practices.

Ford CE, Stickle T.

Discourse Stud. 2012 Feb;14(1):11-30.

Supplemental Content

Support Center